|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Gene Silencing With siRNA (RNA Interference): A New Therapeutic Option During Ex Vivo Machine Liver Perfusion Preservation
Max F. Thijssen
Isabel M. A. Brüggenwirth
Andrew Gillooly
Anastasia Khvorova
Timothy F. Kowalik
Paulo N. Martins
First published: 18 December 2018
https://doi.org/10.1002/lt.25383
Citations: 7
Paulo N. Martins is supported by a UMass Faculty Development Grant and American Association for the Study of Liver Diseases Career in Transplantation Grant.
Anastasia Khvorova consults for Advinc and has intellectual property rights with UMass. Timothy F. Kowalik has stock ownership or equity of more than $10,000 with TATT, LLC, and has intellectual property rights with Moderna and AbViro.
Sections
PDFPDF
Tools
Share
Abstract
RNA interference (RNAi) is a natural process of posttranscriptional gene regulation that has raised a lot of attention culminating with the Nobel Prize in Medicine in 2006. RNAi‐based therapeutics have been tested in experimental transplantation to reduce ischemia/reperfusion injury (IRI) with success. Modulation of genes of the innate immune system, as well as apoptotic genes, and those involved in the nuclear factor kappa B pathways can reduce liver injury in rodent liver pedicle clamping and transplantation models of IRI. However, in vivo use of RNAi faces limitations regarding the method of administration, uptake, selectivity, and stability. Machine perfusion preservation, a more recent alternative approach for liver preservation showing superior results to static cold preservation, could be used as a platform for gene interference therapeutics. Our group was the first to demonstrate uptake of small interfering RNA (siRNA) during liver machine preservation under both normothermic and hypothermic perfusion. Administering siRNA in the perfusion solution during ex vivo machine preservation has several advantages, including more efficient delivery, lower doses and cost‐saving, and none/fewer side effects to other organs. Recently, the first RNAi drug was approved by the US Food and Drug Administration for clinical use, opening a new avenue for new drugs with different clinical applications. RNAi has the potential to have transformational therapeutic applications in several areas of medicine including transplantation. We believe that machine preservation offers great potential to be the ideal delivery method of siRNA to the liver graft, and future studies should be initiated to improve the clinical applicability of RNAi in solid organ transplantation.
|
|
发表于 2020-5-1 13:48
